Related Experiment Video
Updated: Jun 20, 2025
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
Published on: June 14, 2024
CAR-T cell technologies that interact with the tumour microenvironment in solid tumours
Chelsea Alice Taylor1, Maya Glover1, John Maher1,2,3
1Leucid Bio Ltd, Guy's Hospital, London, UK.
Introduction:
Chimeric antigen receptor (CAR) T-cells have emerged as a ground-breaking therapy for the treatment of hematological malignancies due to their capacity for rapid tumor-specific killing and long-lasting tumor immunity. However, the same success has not been observed in patients with solid tumors. Largely, this is due to the additional challenges imposed by safe and uniform target selection, inefficient CAR T-cell access to sites of disease and the presence of a hostile immunosuppressive tumor microenvironment.
Areas Covered:
Literature was reviewed on the PubMed database from the first description of a CAR by Kuwana, Kurosawa and colleagues in December 1987 through to the present day. This literature indicates that in order to tackle solid tumors, CAR T-cells can be further engineered with additional armoring strategies that facilitate trafficking to and infiltration of malignant lesions together with reversal of suppressive immune checkpoints that operate within solid tumor lesions.
Expert Opinion:
In this review, we describe a number of recent advances in CAR T-cell technology that set out to combat the problems imposed by solid tumors including tumor recruitment, infiltration, immunosuppression, metabolic compromise, and hypoxia.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for blood cancers but faces challenges in solid tumors. Engineering CAR T-cells with advanced strategies can improve their effectiveness against solid tumors.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T-cells are effective against hematological malignancies.
- CAR T-cell therapy has limited success in treating solid tumors.
- Challenges include target selection, T-cell infiltration, and the tumor microenvironment.
Purpose of the Study:
- To review recent advances in CAR T-cell technology for solid tumors.
- To address challenges in CAR T-cell therapy for solid tumors.
- To explore strategies for improving CAR T-cell efficacy in solid tumors.
Main Methods:
- Literature review of PubMed database from 1987 to present.
- Focus on studies detailing CAR T-cell engineering for solid tumors.
- Analysis of strategies for tumor recruitment, infiltration, and overcoming immunosuppression.
Main Results:
- CAR T-cells can be engineered with "armoring" strategies.
- These strategies enhance trafficking to and infiltration of solid tumors.
- Reversal of suppressive immune checkpoints is a key advancement.
Conclusions:
- CAR T-cell therapy holds potential for solid tumors with further engineering.
- Advanced strategies are crucial for overcoming solid tumor-specific challenges.
- Future research should focus on optimizing CAR T-cells for solid tumor microenvironments.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...